JP7849587B2 - トリアジンジオン系誘導体、その調製方法及びその医薬的応用 - Google Patents

トリアジンジオン系誘導体、その調製方法及びその医薬的応用

Info

Publication number
JP7849587B2
JP7849587B2 JP2023530323A JP2023530323A JP7849587B2 JP 7849587 B2 JP7849587 B2 JP 7849587B2 JP 2023530323 A JP2023530323 A JP 2023530323A JP 2023530323 A JP2023530323 A JP 2023530323A JP 7849587 B2 JP7849587 B2 JP 7849587B2
Authority
JP
Japan
Prior art keywords
group
groups
general formula
pharmaceutically acceptable
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023530323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550444A5 (cg-RX-API-DMAC7.html
JP2023550444A (ja
Inventor
▲暁▼▲敏▼ ▲張▼
▲偉▼民 胡
洪博 ▲費▼
峰 ▲賀▼
▲維▼康 陶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Pharmaceutical Co Ltd
Publication of JP2023550444A publication Critical patent/JP2023550444A/ja
Publication of JP2023550444A5 publication Critical patent/JP2023550444A5/ja
Priority to JP2026021203A priority Critical patent/JP2026097848A/ja
Application granted granted Critical
Publication of JP7849587B2 publication Critical patent/JP7849587B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023530323A 2020-11-20 2021-11-19 トリアジンジオン系誘導体、その調製方法及びその医薬的応用 Active JP7849587B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026021203A JP2026097848A (ja) 2020-11-20 2026-02-12 トリアジンジオン系誘導体、その調製方法及びその医薬的応用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202011310827 2020-11-20
CN202011310827.4 2020-11-20
CN202110021509.4 2021-01-08
CN202110021509 2021-01-08
CN202110244090 2021-03-05
CN202110244090.9 2021-03-05
CN202110464375 2021-04-28
CN202110464375.3 2021-04-28
PCT/CN2021/131642 WO2022105852A1 (zh) 2020-11-20 2021-11-19 三嗪二酮类衍生物、其制备方法及其在医药上的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026021203A Division JP2026097848A (ja) 2020-11-20 2026-02-12 トリアジンジオン系誘導体、その調製方法及びその医薬的応用

Publications (3)

Publication Number Publication Date
JP2023550444A JP2023550444A (ja) 2023-12-01
JP2023550444A5 JP2023550444A5 (cg-RX-API-DMAC7.html) 2024-05-23
JP7849587B2 true JP7849587B2 (ja) 2026-04-22

Family

ID=81708401

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023530323A Active JP7849587B2 (ja) 2020-11-20 2021-11-19 トリアジンジオン系誘導体、その調製方法及びその医薬的応用
JP2026021203A Pending JP2026097848A (ja) 2020-11-20 2026-02-12 トリアジンジオン系誘導体、その調製方法及びその医薬的応用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026021203A Pending JP2026097848A (ja) 2020-11-20 2026-02-12 トリアジンジオン系誘導体、その調製方法及びその医薬的応用

Country Status (10)

Country Link
US (1) US20240010639A1 (cg-RX-API-DMAC7.html)
EP (1) EP4249474A4 (cg-RX-API-DMAC7.html)
JP (2) JP7849587B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230110538A (cg-RX-API-DMAC7.html)
CN (4) CN119638681A (cg-RX-API-DMAC7.html)
AU (1) AU2021381664B2 (cg-RX-API-DMAC7.html)
CA (1) CA3198934A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005533A (cg-RX-API-DMAC7.html)
TW (1) TW202227420A (cg-RX-API-DMAC7.html)
WO (1) WO2022105852A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510001A (ja) * 2021-03-17 2024-03-05 ハンソー・バイオ・エルエルシー 窒素含有複素環式ケトン、その調製方法及び医薬使用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
IL325304A (en) * 2018-10-29 2026-02-01 Myokardia Inc 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
CN117088854A (zh) * 2022-05-20 2023-11-21 江苏恒瑞医药股份有限公司 一种三嗪二酮类衍生物的可药用盐、晶型及制备方法
WO2023222103A1 (zh) 2022-05-20 2023-11-23 江苏恒瑞医药股份有限公司 一种三嗪二酮类衍生物的晶型及制备方法
WO2024056096A1 (zh) * 2022-09-16 2024-03-21 江苏豪森药业集团有限公司 一种含氮杂环酮化合物的晶型及其制备方法
WO2026130464A1 (zh) * 2024-12-18 2026-06-25 江苏恒瑞医药股份有限公司 制备治疗肥厚型心肌病药物的用途
WO2026153470A1 (zh) * 2025-01-16 2026-07-23 江苏恒瑞医药股份有限公司 制备治疗非梗阻性肥厚型心肌病药物的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012020749A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物
JP2012504575A (ja) 2008-10-09 2012-02-23 エフ.ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
WO2014205234A1 (en) 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
JP2016522263A (ja) 2013-06-21 2016-07-28 マイオカーディア,インク 心臓状態に対するピリミジンジオン化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG173647A1 (en) * 2009-02-13 2011-10-28 Shionogi & Co Novel triazine derivative and pharmaceutical composition containing same
US20110319400A1 (en) * 2010-06-28 2011-12-29 Flores Christopher M Prokineticin 1 receptor antagonists for the treatment of pain
US9663516B2 (en) * 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
IL322175A (en) 2017-08-04 2025-09-01 Myokardia Inc Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds
CN111094300B (zh) * 2018-01-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并杂芳基类衍生物、其制备方法及其在医药上的应用
MA53491A (fr) * 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
IL325304A (en) 2018-10-29 2026-02-01 Myokardia Inc 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione
WO2020151605A1 (zh) * 2019-01-25 2020-07-30 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
CN110698415B (zh) 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
TW202302541A (zh) * 2021-03-17 2023-01-16 美商翰森生物有限責任公司 含氮雜環酮、其製備方法和醫藥用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012504575A (ja) 2008-10-09 2012-02-23 エフ.ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
WO2012020749A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物
WO2014205234A1 (en) 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
JP2016522263A (ja) 2013-06-21 2016-07-28 マイオカーディア,インク 心臓状態に対するピリミジンジオン化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
野崎正勝 等,創薬化学,第1版,株式会社化学同人,1995年,p.98-99

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510001A (ja) * 2021-03-17 2024-03-05 ハンソー・バイオ・エルエルシー 窒素含有複素環式ケトン、その調製方法及び医薬使用

Also Published As

Publication number Publication date
CA3198934A1 (en) 2022-05-27
AU2021381664A1 (en) 2023-06-15
JP2023550444A (ja) 2023-12-01
KR20230110538A (ko) 2023-07-24
CN116323598B (zh) 2024-11-15
CN119638680A (zh) 2025-03-18
EP4249474A4 (en) 2024-04-17
CN119638682A (zh) 2025-03-18
EP4249474A1 (en) 2023-09-27
WO2022105852A1 (zh) 2022-05-27
CN116323598A (zh) 2023-06-23
US20240010639A1 (en) 2024-01-11
AU2021381664B2 (en) 2026-05-28
JP2026097848A (ja) 2026-06-16
TW202227420A (zh) 2022-07-16
MX2023005533A (es) 2023-05-25
CN119638681A (zh) 2025-03-18

Similar Documents

Publication Publication Date Title
JP2023550444A (ja) トリアジンジオン系誘導体、その調製方法及びその医薬的応用
KR100304210B1 (ko) 단백질키나아제c억제제
CN114149423B (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114516843B (zh) 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN116507621B (zh) 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539229B (zh) 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
KR102240158B1 (ko) 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
KR20240046530A (ko) 설폰아미드 유도체, 이의 제조 방법 및 이의 의학적 용도
KR101739361B1 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
JP2018502883A (ja) 拡張型心筋症(dcm)の処置のための4−メチルスルホニル置換ピペリジンウレア化合物
NZ575685A (en) Novel benzofuran potassium channel blockers and uses thereof
CN114456163B (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN101484436A (zh) 作为parp抑制剂的2-氧基杂芳基酰胺衍生物
CN114539257B (zh) 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
JP2025540714A (ja) Lpa受容体活性と関連する状態を処置するための化合物および組成物
KR20150080425A (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
JPS60204785A (ja) フエニルイミダゾール変力剤
WO2008040058A1 (en) Novel chromenone potassium channel blockers and uses thereof
EA048346B1 (ru) Производное триазиндионов, способ его получения и его применение в медицине
HK40095559B (en) Triazine dione derivative, preparation method therefor and application thereof in medicine
HK40095559A (en) Triazine dione derivative, preparation method therefor and application thereof in medicine
WO2025193111A1 (en) An imidazole-indole derivative binding to 5-ht7 serotonin receptor, a pharmaceutical composition comprising the derivative, uses of the derivative and the composition, and an intermediate product for manufacturing the imidazole-indole derivative
CN119039236A (zh) 一种苄胺嘧啶二酮衍生物及其用途
CA3203698A1 (en) 2-pyridone derivative, and preparation method therefor and pharmaceutical application thereof
WO2026041030A1 (zh) 一种尿嘧啶衍生物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240515

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250924

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20251128

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20251201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251128

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20251217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260216

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260316

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260316

R150 Certificate of patent or registration of utility model

Ref document number: 7849587

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150